Safety and effectiveness of an acellular pertussis vaccine in subjects with Down's syndrome
- 29 Downloads
We evaluated the reactogenicity and immunogenicity of an acellular pertussis vaccine in 24 subjects affected by Down's syndrome and in 10 normal infants. Neither general nor local adverse reactions were observed in either group of subjects. The new acellular vaccine administration elicited protective levels of antibodies in all the subjects with Down's syndrome, although the geometric mean titres of IgG antibodies againstBordetella pertussis in these subjects were significantly lower than in normal controls.
Key wordsAcellular pertussis vaccine Down's syndrome Immunization
Unable to display preview. Download preview PDF.
- 2.Cherry JD, Brunell PA, Golden GS, Karzan DT (1988) Report of the task force on “pertussis and pertussis immunization 1988”. Pediatrics 81:933Google Scholar
- 6.Illingworth R (1981) Toxicity of pertussis vaccine. Br Med J 285:210–211Google Scholar
- 11.Preston NW (1994) Pertussis vaccination: neither panic nor complacency. Lancet 2:491–492Google Scholar
- 12.Stewart GT (1979) Toxicity and pertussis vaccine: frequency and possibility of reactions. J Epidemiol Community Health 32:150Google Scholar
- 13.Thomson RG, Rowlins MD, James OFW, Tyrer SP, Codd A (1989) Prevalence of hepatitis B in mental handicap hospital. Lancet 1:44–45Google Scholar